Exozymes Inc. financial data

Symbol
EXOZ on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
750 Royal Oaks Dr, Monrovia, CA
State of incorporation
NV
Fiscal year end
December 31
Former names
Invizyne Technologies Inc (to 1/21/2025)
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Return On Equity -709 % -115%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.37M shares
Common Stock, Shares, Outstanding 8.37M shares +33.9%
Common Stock, Value, Issued 8 USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 6.25M shares +0.04%
Weighted Average Number of Shares Outstanding, Diluted 6.25M shares +0.04%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 723K USD +2490%
General and Administrative Expense 888K USD +144%
Operating Income (Loss) -1.61M USD -311%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.66M USD -218%
Net Income (Loss) Attributable to Parent -5.86M USD -188%
Earnings Per Share, Basic -0.27 USD/shares -238%
Earnings Per Share, Diluted -0.27 USD/shares -238%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.72M USD +14508%
Assets, Current 10.8M USD +792%
Property, Plant and Equipment, Net 882K USD +17.1%
Operating Lease, Right-of-Use Asset 1.33M USD -16.3%
Assets 13M USD +266%
Accounts Payable, Current 924K USD +31.5%
Liabilities, Current 1.33M USD -44.8%
Operating Lease, Liability, Noncurrent 1.16M USD -16.6%
Liabilities 2.61M USD -33.7%
Retained Earnings (Accumulated Deficit) -11.9M USD -96.3%
Stockholders' Equity Attributable to Parent 10.4M USD
Liabilities and Equity 13M USD +266%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 8.37M shares +33.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.72M USD +14508%
Deferred Tax Assets, Valuation Allowance 3.07M USD +59.2%
Operating Lease, Liability 1.39M USD -14%
Depreciation 68.9K USD +38.5%
Lessee, Operating Lease, Liability, to be Paid 1.65M USD
Property, Plant and Equipment, Gross 1.61M USD +32.6%
Operating Lease, Liability, Current 230K USD +2.24%
Lessee, Operating Lease, Liability, to be Paid, Year Two 358K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 349K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 260K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 368K USD
Deferred Tax Assets, Operating Loss Carryforwards 1.31M USD +157%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 379K USD
Additional Paid in Capital 22.4M USD +292%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 482K USD -10.6%
Interest Expense 44.6K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%